These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 8770769)

  • 1. Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen.
    Wang M; Chen PW; Bronte V; Rosenberg SA; Restifo NP
    J Immunother Emphasis Tumor Immunol; 1995 Oct; 18(3):139-46. PubMed ID: 8770769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases.
    Specht JM; Wang G; Do MT; Lam JS; Royal RE; Reeves ME; Rosenberg SA; Hwu P
    J Exp Med; 1997 Oct; 186(8):1213-21. PubMed ID: 9334360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.
    Wang M; Bronte V; Chen PW; Gritz L; Panicali D; Rosenberg SA; Restifo NP
    J Immunol; 1995 May; 154(9):4685-92. PubMed ID: 7722321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens.
    Overwijk WW; Surman DR; Tsung K; Restifo NP
    Methods; 1997 Jun; 12(2):117-23. PubMed ID: 9184376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.
    Bronte V; Tsung K; Rao JB; Chen PW; Wang M; Rosenberg SA; Restifo NP
    J Immunol; 1995 May; 154(10):5282-92. PubMed ID: 7730632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen.
    Chen PW; Wang M; Bronte V; Zhai Y; Rosenberg SA; Restifo NP
    J Immunol; 1996 Jan; 156(1):224-31. PubMed ID: 8598466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.
    Carroll MW; Overwijk WW; Chamberlain RS; Rosenberg SA; Moss B; Restifo NP
    Vaccine; 1997 Mar; 15(4):387-94. PubMed ID: 9141209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing the recognition of tumour associated antigens.
    Restifo NP; Minev BR; Taggarse AS; McFarland BJ; Wang M; Irvine KR
    Folia Biol (Praha); 1994; 40(1-2):74-88. PubMed ID: 7958066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses.
    McCabe BJ; Irvine KR; Nishimura MI; Yang JC; Spiess PJ; Shulman EP; Rosenberg SA; Restifo NP
    Cancer Res; 1995 Apr; 55(8):1741-7. PubMed ID: 7536130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
    Neeley YC; McDonagh KT; Overwijk WW; Restifo NP; Sanda MG
    Prostate; 2002 Nov; 53(3):183-91. PubMed ID: 12386918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.
    Rao JB; Chamberlain RS; Bronte V; Carroll MW; Irvine KR; Moss B; Rosenberg SA; Restifo NP
    J Immunol; 1996 May; 156(9):3357-65. PubMed ID: 8617961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.
    Paglia P; Chiodoni C; Rodolfo M; Colombo MP
    J Exp Med; 1996 Jan; 183(1):317-22. PubMed ID: 8551239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development.
    Charles LG; Xie YC; Restifo NP; Roessler B; Sanda MG
    World J Urol; 2000 Apr; 18(2):136-42. PubMed ID: 10854149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
    Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
    Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector.
    Juillard V; Villefroy P; Godfrin D; Pavirani A; Venet A; Guillet JG
    Eur J Immunol; 1995 Dec; 25(12):3467-73. PubMed ID: 8566039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
    De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
    J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The molecular and functional characterization of a dominant minor H antigen, H60.
    Malarkannan S; Shih PP; Eden PA; Horng T; Zuberi AR; Christianson G; Roopenian D; Shastri N
    J Immunol; 1998 Oct; 161(7):3501-9. PubMed ID: 9759870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes.
    Wu Y; Kipps TJ
    J Immunol; 1997 Dec; 159(12):6037-43. PubMed ID: 9550402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trafficking of tumor peptide-specific cytotoxic T lymphocytes into the tumor microcirculation.
    Ali S; Ahmad M; Lynam J; Rees RC; Brown N
    Int J Cancer; 2004 Jun; 110(2):239-44. PubMed ID: 15069688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.